{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7479,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
      "docSlug": "560176b410a72a6b2e67af5dd2a20758",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "other",
      "function": "establish_context",
      "notes": "The slide uses a grid layout to display logos of various research and clinical partners.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/28",
      "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
      "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
      "docSlug": "560176b410a72a6b2e67af5dd2a20758",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "timeline",
      "function": "show_traction",
      "notes": "The slide uses a chevron-based timeline to distinguish between past achievements (checkmarks) and future goals (dots).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/29",
      "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
      "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 29,
          "beatId": "128bec34-fbcc-431e-ab02-89ccb10153a9",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "The document concludes by highlighting the potential impact of PrimeC and next steps for the company.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
      "docSlug": "560176b410a72a6b2e67af5dd2a20758",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "closing_ask",
      "function": "state_next_steps",
      "notes": "This is the final slide of the deck.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/30",
      "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
      "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-30",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 29,
          "beatId": "128bec34-fbcc-431e-ab02-89ccb10153a9",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "The document concludes by highlighting the potential impact of PrimeC and next steps for the company.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
      "docSlug": "560176b410a72a6b2e67af5dd2a20758",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart shows a clear divergence between the treatment and placebo groups over time, with error bars indicating variability.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/31",
      "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
      "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
      "docSlug": "560176b410a72a6b2e67af5dd2a20758",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart highlights a 13.3% difference at the 180-day mark.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/32",
      "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
      "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
      "docSlug": "560176b410a72a6b2e67af5dd2a20758",
      "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
      "authorId": "neurosense-therapeutics",
      "authorName": "NeuroSense Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various ALS functional domains.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/33",
      "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
      "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/IY2dTgpdRX1Yw5969RFZughdJE2QxxCDMWjqw7w2vLw/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81YzcyOWI0NjQwNzY4NDQ3MzA4MmRjYjljMzlmZTNmYy9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/1",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "e0273d33-87c2-4251-bc5f-c93ae2285c5d",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "The document starts with an overview of Nuvectis Pharma and its pipeline, highlighting the need for new cancer treatments.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": "https://imgproxy.kitesheet.com/XlkDbJ1Fxhqfz78vWjkjuTcAogDVasZ0s-eYxC1rnPs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81YzcyOWI0NjQwNzY4NDQ3MzA4MmRjYjljMzlmZTNmYy9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/-dFHAdSNI2VhV4ul_FxlM60kK6lSi83MsJxkMRh4FSI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81YzcyOWI0NjQwNzY4NDQ3MzA4MmRjYjljMzlmZTNmYy9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/C-LWGLyT8waoKbpTsSEcorpy-oZdbOpxeB18YKMmblo/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81YzcyOWI0NjQwNzY4NDQ3MzA4MmRjYjljMzlmZTNmYy9wMDAxLnBuZw"
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/2",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "e0273d33-87c2-4251-bc5f-c93ae2285c5d",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "The document starts with an overview of Nuvectis Pharma and its pipeline, highlighting the need for new cancer treatments.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/3",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-3",
      "loopMatches": [
        {
          "to": 9,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
          "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
          "position": 0,
          "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "e0273d33-87c2-4251-bc5f-c93ae2285c5d",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "The document starts with an overview of Nuvectis Pharma and its pipeline, highlighting the need for new cancer treatments.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "team_bio",
      "function": "other",
      "notes": "The slide uses a split layout: team members on the left and their associated track record (logos) on the right.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/4",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-4",
      "loopMatches": [
        {
          "to": 9,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
          "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
          "position": 0,
          "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a timeline-based pipeline layout to show the progression of two drug candidates.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/5",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-5",
      "loopMatches": [
        {
          "to": 9,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
          "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
          "position": 0,
          "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/6",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-6",
      "loopMatches": [
        {
          "to": 9,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
          "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
          "position": 0,
          "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/7",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-7",
      "loopMatches": [
        {
          "to": 9,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
          "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
          "position": 0,
          "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a detailed biological pathway diagram created with BioRender.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/8",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-8",
      "loopMatches": [
        {
          "to": 9,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
          "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
          "position": 0,
          "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide demonstrates superior tumor growth inhibition by NXP800 compared to Cisplatin in both resistant and sensitive models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/9",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-9",
      "loopMatches": [
        {
          "to": 9,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
          "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
          "position": 0,
          "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes a patient MRI, a schematic of the PDX study design, a line chart showing tumor volume over time, and photographic evidence of tumor size reduction.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/10",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 10,
          "beatId": "9ba638df-332a-4b15-a2bf-a27225c05ef4",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The document highlights the potential market opportunity for NXP800 and NXP900 in multiple cancers.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide presents preclinical efficacy data for NXP800 in specific genetic subtypes of endometrial cancer.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/11",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 10,
          "beatId": "9ba638df-332a-4b15-a2bf-a27225c05ef4",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The document highlights the potential market opportunity for NXP800 and NXP900 in multiple cancers.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Includes footnotes regarding NGS panels and weighted average calculations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/12",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-12",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 10,
          "beatId": "9ba638df-332a-4b15-a2bf-a27225c05ef4",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The document highlights the potential market opportunity for NXP800 and NXP900 in multiple cancers.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a split-column layout to contrast two phases of a clinical trial.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/13",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-13",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/14",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-14",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/15",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-15",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The charts are kinome dendrograms (KinomeScan style).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/16",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-16",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 16,
          "beatId": "5b4ef0bd-c42a-450a-b62e-0d4bf48a7b12",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Competition",
          "beatSlug": "sequoia-pitch-competition",
          "evidence": "The document presents competitive analysis for NXP900, demonstrating its high selectivity.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a structural biology mechanism of action (MOA) comparison to demonstrate competitive advantage.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/17",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-17",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 16,
          "beatId": "5b4ef0bd-c42a-450a-b62e-0d4bf48a7b12",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Competition",
          "beatSlug": "sequoia-pitch-competition",
          "evidence": "The document presents competitive analysis for NXP900, demonstrating its high selectivity.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/18",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-18",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The charts show tumor regression in NXP900 treated groups versus tumor growth in control groups over 27 days.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/19",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-19",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/20",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-20",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a structured table to segment market opportunity by biological markers.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/21",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-21",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Clinical trial identifier NCT05873686 is provided.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/22",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-22",
      "loopMatches": [
        {
          "to": 22,
          "from": 13,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
          "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
          "position": 1,
          "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "appendix_data",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/23",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 23,
          "from": 23,
          "beatId": "aaac5cb9-1ad5-4c71-ad96-101355c4e382",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Financials",
          "beatSlug": "sequoia-pitch-financials",
          "evidence": "The document provides financial and stock highlights for Nuvectis Pharma.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-883a-72e4-86fb-18270cd4f977",
      "docSlug": "5c729b46407684473082dcb9c39fe3fc",
      "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
      "authorId": "nuvectis-pharma",
      "authorName": "Nuvectis Pharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/24",
      "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
      "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}